Liposome Drug Delivery in Cancer Chemotherapy: Review and Multifactorial Analysis

  • Tatiara Régis
  • Luciana Knop
  • Bruna Machado
  • et al.
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

We reviewed the use of liposomes for cancer therapy using computational biostatistics. We used virtual libraries, such as PubMed, LILACS, National Health Institute (NHI) and the Food Drug Administration (FDA) to conduct the review. Cluster analysis and correlation were developed using the Tanimoto coefficient (TC) of 0.7 using the modeling tool ChemMine Tools from databases (PubChem, DailyMed, DrugBank, Drug @ FDA). The results pointed fifteen molecules in the pharmaceutical form of liposome for the oncological clinic. Of these, 13 are classified by size into small-molecules and were analyzed by computational statistical modeling. Of these, only 4 were approved for use by the FDA, and 9 are in phases of research by the pharmaceutical industry as liposomal formulations. Essential differences in physical-chemical properties and molecules structure were observed, indicating original proposal in the development of liposomal as an anticancer drugs.

Cite

CITATION STYLE

APA

Tatiara Régis, Luciana Knop, Bruna Machado, & Valter de Senna. (2019). Liposome Drug Delivery in Cancer Chemotherapy: Review and Multifactorial Analysis. JOURNAL OF BIOENGINEERING OF AND TECCHNOLOGY Applied to Health, 2(2), 59–69. https://doi.org/10.34178/jbth.v2i2.58

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free